Provided by Tiger Fintech (Singapore) Pte. Ltd.

CureVac B.V.

3.72
+0.18505.24%
Volume:384.25K
Turnover:1.40M
Market Cap:836.45M
PE:4.98
High:3.75
Open:3.55
Low:3.49
Close:3.53
Loading ...

Curevac Is Maintained at Buy by UBS

Dow Jones
·
Yesterday

UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating

MT Newswires Live
·
Yesterday

CureVac Among 3 Promising Penny Stocks To Watch

Simply Wall St.
·
14 Apr

Stock Track | CureVac Shares Soar 5% in Pre-market on Strong 2024 Financial Results and Pipeline Progress

Stock Track
·
11 Apr

CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience

GuruFocus.com
·
11 Apr

Q4 2024 CureVac NV Earnings Call

Thomson Reuters StreetEvents
·
11 Apr

CureVac Stock (CVAC) Dips Despite Promising Treatment Pipeline

TIPRANKS
·
11 Apr

Stock Track | CureVac Shares Plummet 5% Pre-Market on Wider Q4 Losses and Revenue Decline

Stock Track
·
11 Apr

Stock Track | CureVac Shares Plummet 5.03% After Q4 Loss and Mixed 2024 Results

Stock Track
·
11 Apr

CureVac's Cash And Cash Equivalents Position Of €481.7M As Of December 31, 2024; Reaffirming Expected Cash Runway Into 2028

Benzinga
·
10 Apr

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

ACCESS Newswire
·
10 Apr

CureVac Nv - Operating Loss Amounted to EUR 43.8 Mln for Three Months Ended December 31, 2024

THOMSON REUTERS
·
10 Apr

CureVac Nv - Jury Trial in U.S. Litigation Postponed to September 8, 2025

THOMSON REUTERS
·
10 Apr

CureVac Nv - Completed Enrollment of Part B Phase 1 Glioblastoma Study

THOMSON REUTERS
·
10 Apr

CureVac Nv - REV Increase Year-on-Year Was Primarily Driven by New License Agreement With GSK, Which Closed in July 2024

THOMSON REUTERS
·
10 Apr

CureVac Nv - Part B of Gliosblastoma Study First Data Readout Anticipated in H2 2025

THOMSON REUTERS
·
10 Apr

CureVac Nv - Company Reaffirms Its Expected Cash Runway Into 2028

THOMSON REUTERS
·
10 Apr

CureVac Nv - in 2024, Cash Used in Operations Was Mainly Allocated to Extraordinary Payments Amounting to a Total of EUR 137 Mln

THOMSON REUTERS
·
10 Apr

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
10 Apr

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

ACCESS Newswire
·
08 Apr